<DOC>
	<DOCNO>NCT01058707</DOCNO>
	<brief_summary>This Phase I , Open Label , Dose Escalation Study Oral Administration Single Agent MLN0128 Subjects Advanced Malignancies Followed Expansion Subjects renal cell carcinoma , endometrial cancer urothelial cancer measurable disease</brief_summary>
	<brief_title>Dose Escalation Study MLN0128 Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Voluntary write consent Locally advance metastatic solid tumor exception primary brain tumor , fail standard care therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Ability swallow oral medication For woman childbearing potential , negative serum urine pregnancy test within 14 day prior first study drug administration use physicianapproved method birth control 30 day prior 90 day follow last study drug administration Male subject must surgically sterile must agree use physicianapproved contraception study 90 day follow last study drug administration Clinical laboratory value specify protocol Additionally , eligible Dose Expansion portion study : Subjects must evidence measurable disease per RECIST version 1.1 radiographic technique magnetic resonance imaging Subjects must pathologic diagnosis advanced recurrent endometrial adenocarcinoma must fail least 1 prior line standard chemotherapy Subjects must pathologic diagnosis advanced/metastatic urothelial cancer ( carcinoma bladder , ureter , and/or renal pelvis ) must fail least 1 line prior therapy metastatic/unresectable set Subjects must pathologic diagnosis advanced renal cell carcinoma ( RCC ) , histological cytological confirmation RCC must fail least 1 prior line antiVEGF therapy ( include limit sunitinib , and/or sorafenib , and/or bevacizumab and/or pazopanib , and/or axitinib ) must receive prior therapy TORC1 inhibitor ( temsirolimus everolimus ) ; Subjects must pathologic diagnosis advanced renal cell carcinoma ( RCC ) must progress treatment TORC1 inhibitor ( temsirolimus everolimus ) . Diagnosis primary brain tumor Have receive prior cancer investigational therapy within 2 week prior first administration study drug Known impair cardiac function clinically significant cardiac disease Known treatment systemic corticosteroid within one week prior first administration study drug Diabetes mellitus HIV infection Known active cardiovascular disease condition specify protocol Failed recover reversible effect prior anticancer therapy Pregnancy ( positive serum urine pregnancy test ) breast feed Malabsorption due prior gastrointestinal ( GI ) surgery , GI disease Other clinically significant comorbidities Please note additional inclusion exclusion criterion . The study center determine meet criterion . Site personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , site personnel explain reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumor , MLN0128 , TORC1/2 inhibitor</keyword>
</DOC>